Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
Showing 421–480 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
…otherapy, 563 (87.4%) received atezolizumab; 61 (9.5%) received durvalumab. We found that the median OS was 9 months vs 7.2 months (p <0.0…
…aza ML, Otero DC, Magaña J, Bosenberg MW, Swain SL, Bradley LM. PSGL-1 is an immune checkpoint regulator that promotes T cell exhausti…
…comes, and overall survival (OS) in NSCLC patients treated with nivolumab.Methods This observational, multicenter, prospective study enro…
… the incidence and severity of irAEs in melanoma patients using nivolumab, along with the management and outcomes of irAEs, and the overa…
…sent a promising strategy to beneficially shape the microbiota. Lactulose, a non-absorbable prebiotic, has been shown to promote gut heal…
…ery, lesion recurred; C. Ivonescimab treatment for 3 cycles; D. Ivonescimab treatment for 5 cycles…
…5784.References Wolchok JD, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. New England Journal of Me…
…S and suppression of the cGAS-STING axis. Targeting CHCHD3 with TN4510 restores antitumor immunity and enhances neoadjuvant therapy ef…
…ons This FIH study of the novel anti-ROR1 monocloncal antibody, PBA-0405, illustrates the potential of this drug to induce immune cell m…
…llent pathologic responses with only three neoadjuvant doses of cemiplimab. Use of adjuvant radiation was disease-team dependent and in th…
…ctivation cytokines, denoting immune activation by intratumoral urelumab.Conclusions Intratumoral delivery of urelumab is feasible, safe…
…eived conditioning with either fludarabine/cyclophosphamide, or bendamustine, followed by CD4CAR in a 3+3 dose-escalation design. Safety and…